Alnylam Reports Positive Five-Year HELIOS-B Data for Amvuttra

Alnylam Pharmaceuticals reported five-year phase 3 HELIOS-B results showing continuous Amvuttra treatment was associated with a 48% lower risk of death and recurrent cardiovascular events among patients receiving Amvuttra alone, and a 41% reduction across the overall study population, compared with delayed treatment. The company also reported improved heart-health stability and quality of life, with no new safety signals through 60 months. The article did not provide financial results or a stock-price reaction.